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Abstract. Background: Hydantoin derivatives are very
promising candidates to improve the efficacy of anticancer
chemotherapy. Previously, we demonstrated that eight
hydantoin derivatives inhibited the P-glycoprotein (ABCB1)
efflux pump of mouse T-lymphoma cells, as well as acting
synergistically with the anticancer drug doxorubicin.
Materials and Methods: The activity of the hydantoin
derivatives were investigated in another MDR cancer model,
namely Colo 205/S sensitive and Colo 320/R resistant colon
carcinoma cells respectively, having normal or overexpressed
ABCB1 systems. Results: Among the hydantoin derivatives
evaluated, BS-1, MN-3 and JH-63 were the most effective
ABCB1 transporter inhibitors at the concentration of 4 mg/l
on the Colo 320/R cells, compared to the positive control,
verapamil. Conclusion: The derivatives did not induce
apoptosis of Colo 320/R resistant colon carcinoma cells,
indicating that these hydantoin compounds are potent efflux
pump inhibitors (EPI) without affecting the signalling
pathways that regulate apoptosis.
Hydantoin derivatives possess a variety of biochemical and
pharmacological properties. Although hydantoins have been
in use for a long time, the anticancer activity of these
derivatives has received scant attention in the last decades
(1). It has been shown that some 1,5-disubstituted hydantoins
inhibit epidermal growth factor receptor (EGFR)
autophosphorylation and proliferation of human A431 cells
that overexpress EGFR (2, 3). Natural hydantoin compounds
are gaining attention as well: phenyl-methylene hydantoins
(PMH), guanidine alkaloids derived from Red Sea sponges,
have the ability to increase cell-cell adhesion in prostate
cancer cells and reduce invasion, furthermore they have
potent in vitro and in vivo anti-growth and anti-invasive
properties against PC-3M prostate cancer cells (4, 5). In
colon adenocarcinoma cells, 5,5-diphenyl-2-thiohydantoin-
N10 (DPTH-N10) inhibited proliferation, but did not cause
the death of Colo 205 cells (6). Recent studies have shown
that some diversely substituted diazaspiro hydantoins had an
antiproliferative effect against MCF-7 breast carcinoma,
HepG-2 hepatocellular carcinoma, HeLa cervix carcinoma
and HT-29 colon carcinoma cell lines (7).
Previously, we evaluated thirty hydantoin compounds for
modulation of the activity of the transporter P-glycoprotein
(after the new nomenclature ATP-binding cassette, subfamily
B, member 1 transporter or ABCB1) of mouse T-lymphoma
cells (8). Among the selected derivatives, some significantly
increased the retention of rhodamine 123. Compounds AD-
26, AD-29, RW-13, BS-1, MN-3, RW-15b and KF-2 showed
synergistic effect with doxorubicin on mouse lymphoma
cells. These results indicated the role of chemical
modifications within the hydantoin ring for its potential
inhibition of the ABCB1 transporter. The most active
structures contained aromatic substituents as well as some
tertiary amine fragments (8).
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In this current study, the ABCB1 efflux pump modulating
effect of the previously selected hydantoin derivatives was
investigated in Colo 205/S sensitive colon carcinoma cells
with normal ABCB1 expression pattern and Colo 320/R
multidrug resistant (MDR) colon carcinoma cells having an
overexpressed ABCB1 system. The apoptosis inducing effect
of these derivatives was also examined.
Materials and Methods
Compounds. Eight hydantoin derivatives (SZ-7, BS-1, JH-63, MN-
3, RW-15b, AD-26, RW-13, AD-29) were tested, kindly provided by
Dr. Jadwiga Handzlik and Prof. Dr. Katarzyna Kiec-Kononowicz,
Cracow, Poland. The compounds were dissolved in DMSO.
Cell lines. The human colon adenocarcinoma cell lines (Colo 205
doxorubicin sensitive parent and Colo 320/MDR-LRP resistant to
anticancer agents overexpressing ABCB1(MDR1)-LRP), ATCC-
CCL-220.1 (Colo 320) and CCL-222 (Colo 205), were purchased
from LGC Promochem, Teddington, England.
The cells were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1
mM Na-pyruvate and 100 mM Hepes. The cells were incubated in a
humidified atmosphere (5% CO2, 95% air) at 37˚C. The semi-
adherent cancer cells were detached with 0.25% trypsin and 0.02%
EDTA for 5 min at 37˚C.
Assay for antiproliferative and cytotoxic effect. The effects of
increasing concentrations of the drugs alone on cell growth were
tested in 96-well flat-bottomed microtitre plates. The compounds
were diluted in a volume of 100 μl medium. Then, 6×103 (for
antiproliferative assay) or 2×104 cells (for cytotoxic assay) in 50 μl
of medium, respectively, were added to each well, with the exception
of the medium control wells. The culture plates were further
incubated at 37˚C for 24 and 72 h, respectively; at the end of the
incubation period, 15 μl of MTT (thiazolyl blue tetrazolium bromide,
Sigma-Aldrich Chemie GmbH, Steinheim) solution (from a 5 mg/ml
stock) was added to each well. After incubation at 37˚C for 4 h, 100
μl of sodium dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M
HCl) was added to each well and the plates were further incubated at
37˚C overnight. Cell growth was determined by measuring the optical
density (OD) at 550 nm (ref. 630 nm) with a Multiscan EX ELISA
reader (Thermo Labsystems, Cheshire, WA, USA).
Inhibition of the cell growth was determined according to the
formula:
Where IC50 is defined as the inhibitory dose that reduces the growth
of the compound-exposed cells by 50%.
Flow cytometry assay. Functional analysis of the ABCB1 transporter
can be accomplished using flow cytometric accumulation assays
with fluorescent dyes (9); for this purpose the intracellular
accumulation of the non-toxic fluorescent ABCB1 (P-glycoprotein)
substrate rhodamine 123 by the Colo 320 cells with an
overexpressed ABCB1 efflux system was studied. This assay has
been fully described previously (10). Briefly, the cells were adjusted
to a density of 2×106/ml, re-suspended in serum-free RPMI 1640
medium and distributed in 0.5 ml aliquots into Eppendorf centrifuge
tubes. The test compounds (10 μl) were added at various
concentrations and the samples were incubated for 10 min at room
temperature. Next, 10 μl (5.2 mM final concentration) of rhodamine
123 was added to the samples and the cells were incubated for a
further 20 min at 37˚C, washed twice and re-suspended in 0.5 ml
phosphate-buffered saline (PBS) for analysis. The fluorescence
uptake of the cell population was measured with a FACStar Plus
flow cytometer (Beckton, Dickinson and Company, Franklin Lakes,
NJ, USA). Verapamil was used as a positive control in the
rhodamine 123 exclusion experiments. The percentage mean
fluorescence intensity was calculated for the treated MDR Colo 320
and sensitive Colo 205 cells as compared to untreated cells. A
fluorescence activity ratio (FAR) was calculated via the following
equation, on the basis of the measured fluorescence values.
The results obtained from a representative flow cytometry
experiment in which 10,000 individual cells of the population were
evaluated for the quantity of rhodamine 123 retained with the aid of
the Beckton Dickinson FACStar flow cytometer, were first presented
as histograms and the data was converted to FAR units that define
fluorescence intensity, standard deviation, peak channel in the total-
and in the gated- populations.
Assay for apoptosis induction. The assay was carried out using an
Annexin V-FITC Apoptosis Detection Kit Cat. No. PF 032 from
Calbiochem (EMD Biosciences, Inc. La Jolla, CA) according to the
manufacturer’s instructions.
The concentration of the cell suspension was adjusted to
approximately 1×106 cells/ml. The cell suspension was distributed
into 0.5 ml aliquots (5×105 cells) into a 24-well microplate and
incubated overnight, at 37˚C, 5% CO2. On the following day the
medium was removed and fresh medium was added to the cells. The
cells were incubated in the presence of the hydantoin derivatives for
3 hours at 37˚C; the concentration for the apoptosis induction (4 or
40 mg/l) were selected based on previous results (8).12H-
benzo[α]phenothiazine was used as positive control at a final
concentration of 50 μg/ml. The culture medium was removed, the
cells were washed with PBS and fresh medium was added to the
cells. The 24-well plates were incubated overnight at 37˚C, 5% CO2.
After the incubation the supernatant was collected in a microfuge
tube and 200 μl of 0.25 trypsin (Trypsin-Versen) was added to the
wells until the cells detached from the surfaces of the wells. After the
addition of culture medium, the cells were centrifuged at 2000 × g
for 2 min at room temperature, the supernatant was removed and the
cells were re-suspended in fresh serum-free medium. 
After this procedure, the apoptosis assay was carried out
according to the rapid protocol of the kit. The other conditions
including AnnexinV-FITC and propidium iodide controls were
applied as described elsewhere (11). The fluorescence was analysed
immediately using a Becton Dickinson FACStar flow cytometer.
Results
As shown in Table I, after determination of the IC50 values,
the hydantoin derivatives had more potent anti-proliferative
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effect on the MDR Colo 320 cells than on the sensitive Colo
205 cells. The compounds AD-26 and AD-29 were more
cytotoxic on the MDR Colo 320 cells compared to the
sensitive Colo 205 cells.
Based on the flow cytometric evaluation, all of the
compounds inhibited the activity of the ABCB1 transporter
(Table II). The derivatives BS-1, MN-3 and JH-63 were the
most effective inhibitors at the concentration of 4 mg/l on
the Colo 320/R cells compared to the positive control
verapamil. As demonstrated in Table III, the selected
hydantoin derivatives did not induce apoptosis in the Colo
320/R cells compared to the positive control 12H-
benzo[α]phenothiazine. The proportion of early and late
apoptotic cells was not changed after incubation with the
hydantoin derivatives, indicating that these derivatives did
not posses apoptosis inducing activity.
Discussion
Hydantoin analogs have been reported as potent anti-tumour
agents (1-8), furthermore the apoptosis inducing activity of
some hydantoin derivatives has been demonstrated (6, 12,
13). Previously, a series of novel 5-arylidene-2-
arylaminothiazol-4(5H)-ones and 2-aryl(benzyl)amino-1H-
imidazol-4(5H)-ones were evaluated for anticancer properties
and the majority of these compounds showed significant
antitumour cytotoxic effects at the micromolar and
submicromolar level (14). Increasing evidence suggests that
some hydantoin derivatives can induce apoptosis in various
tumour cell lines (6, 12, 13). Previously, the selected eight
derivatives were shown not to induce apoptosis of L5178Y
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Table I. Antiproliferative and cytotoxic effects of hydantoin derivatives
on Colo 205/S and Colo 320/R colon adenocarcinoma cells. 
Antiproliferative effect Cytotoxic effect
μg/ml μg/ml
Colo 205 Colo 320 Colo 205 Colo 320
SZ-7 14.9 8.8 28.3 33.6
BS-1 22.4 21.2 44.7 67.2
JH-63 36.6 22.9 39.9 84.8
MN-3 20.9 13.5 31.5 36.5
RW-15b 32.4 17.3 43.9 42.5
AD-26 17.3 8.3 45.9 35.8
RW-13 26.3 11.2 50.4 48.3
AD-29 23.9 14.5 52.5 31.6
DMSO 8.4% 9.7% 3.1% 0.8%
Table II. Effect of hydantoin derivatives on rhodamine 123 retention by
Colo 320/R colon adenocarcinoma cells.
Samples μg/ml FSC SSC FL-1 FAR
Colo 205 - 456.93 255.18 1061.97 -
Colo 205 - 451.93 258.98 1051.21 -
Colo 320 - 462.79 273.89 98.83
Colo 320 - 445.59 274.50 61.77 -
Colo 320 (mean) 80.3
Verapamil 10 456.49 267.55 298.20 3.71
SZ-7 4 451.37 261.31 246.40 3.07
SZ-7 40 433.56 286.43 565.24 7.04
BS-1 4 436.49 267.53 1073.13 13.36
BS-1 40 418.93 265.36 1079.71 13.44
JH-63 4 441.80 273.48 850.05 10.59
JH-63 40 431.41 272.49 792.07 9.86
MN-3 4 433.35 264.46 676.06 8.41
MN-3 40 425.09 257.94 1011.00 12.59
RW-15b 4 434.72 273.80 79.41 0.98
RW-15b 40 427.51 271.01 133.30 1.66
AD-26 4 435.91 270.97 239.68 2.98
AD-26 40 431.00 269.75 709.54 8.83
RW-13 4 447.03 278.66 316.33 3.93
RW-13 40 438.97 269.12 562.99 7.01
AD-29 4 448.88 282.65 145.85 1.81
AD-29 40 443.51 269.72 406.22 5.06
DMSO 4% 433.16 270.89 65.94 0.82
FSC: Forward scatter count of cells in the samples (cell size ratio); SSC:
side scatter count of cells in the samples; FL-1: mean fluorescence
intensity of the cells. FAR: Fluorescence activity ratio.
Table III. Apoptosis inducing activity of selected hydantoin derivatives,
after 3 hours of incubation on Colo 320/R colon adenocarcinoma cells.
A+: Annexin V-FITC staining, A–: without Annexin V-FITC, I+:
propidium iodide staining, I–: without propidium iodide 
Gated events %
Conc. Early Late Cell 
μg/ml apoptosis apoptosis  death 
% and necrosis %
%
Control A–I– 0 0 0.40
Control A–I+ 0 0 3.24
Control A+I– 0.52 0 0.19
Control A+I+ 5.36 1.31 0.34
DMSO 1% 8.02 1.64 0.40
12H-benzo[α]phenothiazine 50 18.57 18.25 7.70
SZ-7 4 1.56 0.67 1.38
BS-1 4 4.39 1.86 0.37
JH-63 4 0.42 0.26 1.65
MN-3 4 0.44 0.12 0.72
RW-15b 40 1.83 0.77 0.73
AD-26 40 2.24 1.04 0.85
RW-13 40 1.36 0.81 0.57
AD-29 40 0.70 0.36 0.52
Control A–I– 0 0 0.02
Note. Compounds that had maximum activity on the efflux pump (Table
II) at concentration of 4 μg/ml tested only at this concentration for
apoptosis. 
mouse T-cell lymphoma cells over-expressing the ABCB1
system compared to the positive control 12H-
benzo[α]phenothiazine (unpublished results), even though
the hydantoin derivatives inhibited the ABCB1 multidrug
transporter system of the mouse T-lymphoma cells (8).These
derivatives increased the intracellular accumulation of
rhodamine 123 in the MDR Colo 320 cells, they were potent
ABCB1 inhibitors. Furthermore, the studied hydantoin
analogs did not induce the apoptosis of the Colo 320 cells
after 180 minutes of incubation, indicating that these
hydantoin compounds are potent efflux pump inhibitors
(EPI) without affecting the signalling pathways that regulate
apoptosis. Taking into consideration that hydantoin analogs
SZ-7, BS-1, JH-63, MN-3, RW-15b, AD-26, RW-13 and AD-
29 can inhibit the ABCB1 transporter, the mode of action of
these derivatives should be clarified by further studies.
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